WaVe生命科學 WVE 深 滬
等待開盤 09-17 09:30:00 美东时间
6.82
-0.150
-2.15%
華盛通- 最 高7.025
- 今 開6.95
- 成交量 149.53万股
- 最 低 6.79
- 昨 收 6.97
- 總市值 10.50亿
- 52周最高 16.735
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 5.28
- 委 比 -7.14%
- 總股本 1.54亿
- 歷史最高 56.00
- 量 比 0.81
- 振 幅 3.37%
- 歷史最低 1.16
- 每 手 1
- 風險率 1.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Peering Into WAVE Life Sciences's Recent Short Interest
WAVE Life Sciences's (NYSE:WVE) short interest as a percent of float has risen ...
09-13 04:01
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Wave Life Sciences Announces Data From 200 Mg Single And Multidose And 400 Mg Single Dose Cohorts Of Ongoing Phase 1b/2a Restoraation-2 Study Evaluating WVE-006 As Treatment For AATD
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever
09-03 19:32
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences announced positive results from the Phase 1b/2a RestorAATion-2 study of WVE-006 for alpha-1 antitrypsin deficiency (AATD). Data showed significant increases in wild-type M-AAT protein, reductions in mutant Z-AAT, and supportive safety profile, enabling monthly or less frequent dosing. WVE-006 demonstrated the ability to restore physiological AAT production, including during an acute phase response. Further data from the 400 mg ...
09-03 11:30
Wave Life Sciences gains as JPMorgan suspends rating
Wave Life Sciences (NASDAQ:WVE) quickly hit highs of the day, rising 5%, after JPMorgan suspended its rating, price target, and estimates on the company. Some investors may be speculating that JPMorg...
08-16 00:43
Wave Life Sciences Shareholders Approve Key Proposals
An update from Wave Life Sciences ( ($WVE) ) is now available. On August 5, 202...
08-12 05:50
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswir...
08-07 07:56
Wells Fargo Maintains Overweight on WAVE Life Sciences, Lowers Price Target to $21
Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from $24 to $21.
07-31 23:46
